NapeƱas, Servando .
HRN: 17-47-23 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/12/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
11/12/2024
11/19/2024
IV
2.25g
Q8
Complicated Uti
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes